? The National Surgical Adjuvant Breast and Bowel Project (NSABP) is an NCI-funded, organ-specific multicenter cooperative trials group whose main goal is to conduct Phase III clinical trials in patients with primary breast and colorectal cancer. ? ? The NSABP Human Specimen Bank collects, processes, stores and provides access to high quality specimens obtained from patients entered into NSABP trials. These specimens are carefully linked to the patient's clinical, treatment, recurrence, and outcome data while fully protecting the confidentiality of patients. The scientific aim of the NSABP Human Specimen Bank is to support translational research by providing open access to these well-used annotated specimens in order to facilitate the development of prognostic and predictive markers that can be used to custom-tailor treatment of breast and cotorectal cancer. Specimens from the Bank may also aid in the development of molecular signatures, identification of therapeutic targets, and other important transitional studies. With a Tissue Bank of paraffin blocks from more than 40,000 cases, some dating back to 1971, with the addition of 3,500 cases or more each year, along with a new initiative to collect specimens in RNAlater(r) to support RNA-based studies, the NSABP is certainly able to deliver on that promise. ? ? In an effort to further improve access to the NSABP Human Specimen Bank, tissue microarrays (TMAs) from key trials in both breast and colon cancers are being offered to the general scientific community in collaboration with the Resources Development Branch (RDB) of the NCI. The NSABP will also work with the Group Banking Committee to develop policies relating to human specimen banking in NCI-supported cancer clinical trials. ? ? Continued support of these relevant, important activities is essential for the well-being of cancer patients and is critical to the success of both the NSABP's and the NCI's missions. ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Resource-Related Research Projects--Cooperative Agreements (U24)
Project #
5U24CA114732-03
Application #
7209752
Study Section
Special Emphasis Panel (ZCA1-SRRB-3 (J1))
Program Officer
Lubensky, Irina
Project Start
2005-05-27
Project End
2010-03-31
Budget Start
2007-04-01
Budget End
2008-03-31
Support Year
3
Fiscal Year
2007
Total Cost
$866,285
Indirect Cost
Name
Nsabp Foundation, Inc.
Department
Type
DUNS #
107186988
City
Pittsburgh
State
PA
Country
United States
Zip Code
15212
Ingle, James N; Kalari, Krishna R; Wickerham, Donald Lawrence et al. (2018) Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab. Pharmacogenet Genomics 28:147-152
Margolese, Richard G; Cecchini, Reena S; Julian, Thomas B et al. (2016) Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet 387:849-56
Dalerba, Piero; Sahoo, Debashis; Paik, Soonmyung et al. (2016) CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. N Engl J Med 374:211-22
Wolmark, Norman; Mamounas, Eleftherios P; Baehner, Frederick L et al. (2016) Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/Nati J Clin Oncol 34:2350-8
Ganz, Patricia A; Cecchini, Reena S; Julian, Thomas B et al. (2016) Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet 387:857-65
Chapman, Judith-Anne W; Costantino, Joseph P; Dong, Bin et al. (2015) Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29. Breast Cancer Res Treat 153:353-60
Ingle, James N (2013) Pharmacogenomics of endocrine therapy in breast cancer. J Hum Genet 58:306-12
Pogue-Geile, Kay; Yothers, Greg; Taniyama, Yusuke et al. (2013) Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08. J Natl Cancer Inst 105:989-92
Ingle, James N; Liu, Mohan; Wickerham, D Lawrence et al. (2013) Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention. Cancer Discov 3:812-25
McCahill, Laurence E; Yothers, Greg; Sharif, Saima et al. (2012) Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10. J Clin Oncol 30:3223-8

Showing the most recent 10 out of 26 publications